Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022)
Annals of Internal Medicine · 2024-10 · 177 (10) · 1442-1444
DOI: 10.7326/annals-24-00614 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Internal Medicine, 2024-10. Verfasst von Camille E G Glaus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Abstract (Originalsprache)
ZORA (Zurich Open Repository and Archive) provides open and worldwide access to the research and scholarly output of the University of Zurich, Switzerland. A focus is on qualified scientific publications. ZORA is operated by the University Library together with the Central IT of the University of Zurich.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
- Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
- Professor of Health Policy and Ingram Professor of Cancer Research, Vanderbilt University School of Medicine, Department of Health Policy, and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
- Professor of Law and Medicine, Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Miquel Serra-Burriel, Stacie B Dusetzina
Zitieren
APA
Glaus, C. E. G., Serra-Burriel, M., Dusetzina, S. B., & Vokinger, K. N. (2024). Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022). Annals of Internal Medicine, 177(10), 1442-1444. https://doi.org/10.7326/annals-24-00614
Vancouver
Glaus CEG, Serra-Burriel M, Dusetzina SB, Vokinger KN. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022). Annals of Internal Medicine. 2024;177(10):1442-1444. doi:10.7326/annals-24-00614
BibTeX
@article{Glaus2024,
author = {Glaus, Camille E G and Serra-Burriel, Miquel and Dusetzina, Stacie B and Vokinger, Kerstin N},
title = {Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022)},
journal = {Annals of Internal Medicine},
year = {2024},
volume = {177},
number = {10},
pages = {1442--1444},
doi = {10.7326/annals-24-00614}
}
EUVIMED